Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(25 sites)

United Kingdom

Royal United Hospital, Bath, Bath

The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Bournemouth

East Kent Hospitals University NHS Foundation Trust, Canterbury

University Hospital of Wales, Cardiff

Colchester Hospital, Colchester

Mid Yorkshire NHS Trust, Dewsbury

Royal Devon University Hospital, Exeter

Medway Maritime Hospital, Gillingham

Castle Hill Hospital, Hull

NHS Lanarkshire, Lanark

St James's University Hospital, Leeds

Leicester Royal Infirmary, Leicester

Barking, Havering and Redbridge University Hospitals NHS Trust, London

Barts Health NHS Trust, London

King's College Hospital, London

Northwick Park Hospital, London

University College London Hospitals NHS Foundation Trust, London

Christie NHS Foundation Trust, Manchester

Norfolk and Norwich Hospital, Norwich

Oxford University Hospital, Oxford

University Hospitals Plymouth NHS Trust, Plymouth

Salisbury NHS Foundation Trust, Salisbury

Torbay & Newton Abbot Hospital, Torquay

Royal Cornwall Hospital, Truro

Hampshire Hospitals NHS Foundation Trust, Winchester